Integrated Neuromodulation System for Mood Enhancement of a Living Human Subject

• US 20140106014A1
• Filed: 12/13/2013
• Published: 04/17/2014
• Est. Priority Date: 10/04/2012
• Status: Active Grant

• Current Assignee: Invivo Beverages LLC
• Original Assignee: Invivo Beverages LLC
• Inventors: Giuliano, Vincent, Manley, James
• Granted Patent: US 9,114,140 B2
• Time in Patent Office: Days
• US Class Current: 424/757
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/133 having hydroxy groups, e.g. sphingosine
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61K 36/41 Crassulaceae (Stonecrop family)
• CPC Class Codes: A61K 36/48 Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system

Abstract

The present invention is an ingestable blended formulation which will cause a series of distinct biochemical changes in-vivo; initiate desirable psychological consequences in that person; and induce an observable increase in cognitive functions for that living human subject. In particular, the initiated psychological events will generate a positive change in one'"'"'s personal perceptions, evoke optimism as the subjective state of mind, and elicit a more sociable attitude and favorable mood as the observable behavior of the affected human person. Moreover, in addition to the initiation of a more positive state of mind, another major result and effect of ingesting the blended formulation is an observable amplification of human brain functions and a substantive increase of human concentration, focus and memory.

Claims

1. A method for initiating an improvement of human mood and inducing an observable enhancement of cognitive functions in a living human subject, said method comprising the steps of:

obtaining a non-prescription blended formulation suitable for oral ingestion by a living human subject, said blended formulation being a controlled nootropic admixture consisting of five different kinds of essential nootropic active ingredients, each of which is able to pass the blood-brain barrier in-vivo, said controlled nootropic admixture having

(a) not less than two different naturally existing nootropic dopamine neurotransmitter agonists,

(b) not less than one naturally existing nootropic acetylecholine neurotransmitter agonist,

(c) not less than one naturally existing nootropic serotonin neurotransmitter agonist,

(d) not less than one naturally existing nootropic gamma-aminobutyric acid (GABA) neurotransmitter agonist, and

(e) at least one nootropic adenosine antagonist,

wherein the ratio of all individual nootropic neurotransmitter agonists to all individual nootropic adenosine antagonists is proportionally not less than 5;

1, and

wherein the neurotransmitter replenishment balance for the admixture of essential active agents mathematically is zero (“

0”

) in value, and

wherein there is a complete absence of any other kind of nootropic agonist or antagonist;

orally administering said blended formulation to a living human subject in a predetermined quantity sufficient to initiate an improvement of human mood and induce an observable enhancement of cognitive functions in a living human subject;

allowing at least a minimal time period after ingestion for said orally administered quantity of blended formulation to become assimilated by and to act within the body of said living human subject;

periodically monitoring the human subject for objective indications of a positive mental state and an observable enhancement of cognitive functions; and

determining from said objective indications that a more positive mental state exists and an observable enhancement of cognitive functions has occurred in the living human subject.

3. The method recited in claim 1 or 2 whereby a series of distinct biochemical changes are caused in the living human subject.

4. The method recited in claim 3 whereby concurrent stimulation of dopamine, serotonin, GABA, and acetylcholine receptors, with simultaneous reversible adenosine receptor blockade, is caused in-vivo.

5. The method recited in claim 1 or 2 whereby psychological consequences are initiated in the living human subject.

6. The method recited in claim 5 wherein said psychological consequences initiated in the living human subject are at least one selected from the group consisting of inducing a positive change in one'"'"'s personal perceptions, evoking optimism as the subjective state of mind, and eliciting a more sociable attitude.

7. The method recited in claim 1 or 2 whereby improvements in human cognitive brain functions are found in the living human subject.

8. The method as recited in claim 7 wherein said improvements in human cognitive brain functions found in the living human subject are at least one selected from the group consisting of acquiring information, gathering and selecting, representing and comprehending, retaining and recalling information, and using recollection to direct and guide behavior.

9. The method recited in claim 1 or 2 whereby an amplification of human concentration and an increase of human memory are instituted in the living human subject.

10. The method recited in claim 1 or 2 wherein said orally administered blended formulation becomes assimilated and acts within the body of the living human subject within 5-40 minutes time.

11. The method recited in claim 1 or 2 wherein said periodic monitoring of the living human subject for objective indications of a positive mental state and an observable enhancement of cognitive functions is made by qualitative assessment scoring.

12. The method recited in claim 1 or 2 wherein said determining from objective indications that a more positive mental state exists and an observable enhancement of cognitive functions has occurred in the living human subject is made by qualitative assessment testing.

13. The method recited in claim 1 or 2 wherein the expected duration of induced effects ranges from about 2 to about 8 hours.

14. The method recited in claim 1 or 2 wherein the age of the living human subject ranges from 14 to 80 years.

2. A method for initiating an improvement of human mood and inducing an observable enhancement of cognitive functions in a living human subject, said method comprising the steps of:

obtaining a non-prescription blended formulation suitable for oral ingestion by a living human subject, said blended formulation being a controlled nootropic admixture consisting of five different kinds of essential nootropic active ingredients, each of which is able to pass the blood-brain barrier in-vivo, said controlled nootropic admixture having

(a) not less than two and not more than six different naturally existing nootropic dopamine neurotransmitter agonists,

(b) not less than one and not more than four naturally existing nootropic acetylecholine neurotransmitter agonists,

(c) not less than one and not more than three naturally existing nootropic serotonin neurotransmitter agonists,

(d) not less than one and not more than three naturally existing nootropic gamma-aminobutyric acid (GABA) neurotransmitter agonists, and

(e) at least one and not more than three nootropic adenosine antagonists,

wherein the ratio of all individual nootropic neurotransmitter agonists to all individual nootropic adenosine antagonists is proportionally not less than 5;

1 and not more than 16;

1, and

wherein the neurotransmitter replenishment balance for the admixture of essential active agents mathematically is zero (“

0”

) in value, and

wherein there is a complete absence of any other kind of nootropic agonist or antagonist;

orally administering said blended formulation to a living human subject in a predetermined quantity sufficient to initiate an improvement of human mood and induce an observable enhancement of cognitive functions in a living human subject;

allowing at least a minimal time period after ingestion for said orally administered quantity of blended formulation to become assimilated by and to act within the body of said living human subject;

periodically monitoring the human subject for objective indications of a positive mental state and an observable enhancement of cognitive functions; and

determining from said objective indications that a more positive mental state exists and an observable enhancement of cognitive functions has occurred in the living human subject.